A Mesenchymal Stem Cell Potency Assay
Mesenchymal stem cells (MSCs) are capable of modulating the immune system and have been used to successfully treat a variety of inflammatory diseases in preclinical studies. Recent evidence has implicated paracrine signaling as the predominant mechanism of MSC therapeutic activity. We have shown in models of inflammatory organ failure that the factors secreted by MSCs are capable of enhancing survival, downregulating inflammation, and promoting endogenous repair programs that lead to the reversal of these diseases. As a marker of disease resolution, we have observed an increase in serum IL-10 when MSC-conditioned medium (MSC-CM) or lysate (MSC-Ly) is administered in vivo. Here we present an in vitro model of IL-10 release from blood cells that recapitulates this in vivo phenomenon. This assay provides a powerful tool in analyzing the potency of MSC-CM and MSC-Ly, as well as characterizing the interaction between MSC-CM and target cells in the blood.
Key wordsMesenchymal stem cell IL-10 Potency assay Organ injury Inflammation Auto-immunity Transplantation
This work was partially supported by grants from the National Institutes of Health (R01 DK43371), MIT Class of 1972 Fund, and the Shriners Hospitals for Children.
- 3.Bartholomew, A., C. Sturgeon, M. Siatskas, K. Ferrer, K. McIntosh, S. Patil, W. Hardy, S. Devine, D. Ucker, R. Deans, A. Moseley, R. Hoffman. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology 30.1 (2002): 42–48.PubMedCrossRefGoogle Scholar
- 4.Ringden, O., M. Uzunel, I. Rasmusson, M. Remberger, B. Sundberg, H. Lonnies, HU Marschall, A. Dlugosz, A. Szakos, Z. Hassan, B. Omazic, J. Aschan, L. Barkholt, K. Le Blanc. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81.10 (2006): 1390–397.PubMedCrossRefGoogle Scholar
- 5.Perin, E. C., H. F. Dohmann, R. Borojevic, S. A. Silva, A. L. Sousa, C. T. Mesquita, M. I. Rossi, A. C. Carvalho, H. S. Dutra, H. J. Dohmann, G. V. Silva, L. Belem, R. Vivacqua, F. O. Rangel, R. Esporcatte, Y. J. Geng, W. K. Vaughn, J. A. Assad, E. T. Mesquita, J. T. Willerson. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107.18 (2003): 9040–42.CrossRefGoogle Scholar
- 6.Miyahara, Y., N. Nagaya, M. Kataoka, B. Yanagawa, K. Tanaka, H. Hao, K. Ishino, H. Ishida, T.Shimizu, K. Kangawa, S. Sano, T. Okano, S. Kitamura, H. Mori. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nature Medicine 12 (2006): 459–65.PubMedCrossRefGoogle Scholar
- 7.Jin, H. K., J. E. Carter, G. W. Hungtley, E. H. Schuchman. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. Journal of Clinical Investigation 109.9 (2002): 1183–191.PubMedGoogle Scholar
- 10.Horwitz, E. M., D. J. Prockop, L. A. Fitzpatrick, W. W. Koo, P. L. Gordon, M. Neel, M. Sussman, P. Orchard, J. C. Marx, R. E. Pyeritz, M. K. Brenner. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Medicine 5 (1999): 309–13.PubMedCrossRefGoogle Scholar
- 11.Gnecchi, M., H. He, N. Noiseux, O. D. Liang, L. Zhang, F. Morello, H. Mu, L. G. Melo, R. E. Pratt, J. S. Ingwall, V. J. Dzau. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. The FASEB Journal 20 (2006): 661–69.CrossRefGoogle Scholar
- 13.Kinnarid, T., E. Stabile, M. S. Burnett, C. W. Lee, S. Barr, S. Fuchs, S. E. Epstein. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Research 94 (2004): 678–85.CrossRefGoogle Scholar
- 16.Németh, K., A. Leelahavanichkul, P. S. Yuen, B. Mayer, A. Parmelee, K. Doi, P. G. Robey, K. Leelahavanichkul, B. H. Koller, J. M. Brown, X. Hu, I. Jelinek, R. A. Star, É. Mezey. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine 15 (2008): 42–49.PubMedCrossRefGoogle Scholar
- 19.Parekkadan, B. Cellular and molecular immunotherapeutics derived from the bone marrow stroma. Massachusetts Institute of Technology, Doctoral Thesis (2008).Google Scholar
- 20.Lazarus, H., O. Koc, S. Devine, P. Curtin, R. Maziarz, H. Holland, E. Shpall, P. McCarthy, K. Atkinson, B. Cooper. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation 11.5 (2005): 389–98.PubMedCrossRefGoogle Scholar
- 21.Baba, S. Clinical trials of regeneration for periodontal tissue. Home – ClinicalTrials.gov. (2005). Web. 18 Aug 2009. <http://clinicaltrials.gov/ct2/show/NCT00221130>.
- 22.Kastrup, J. Stem cell therapy for vasculogenesis in patients with severe myocardial ischemia. Home – ClinicalTrials.gov. (2005). Web. 18 Aug 2009. <http://clinicaltrials.gov/ct2/show/NCT00260338>.
- 24.Bianco, P., S. A. Kuznetsov, M. Riminucci, L. W. Fisher, A. M. Spiegel, P. G. Robey. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gs a-mutated skeletal progenitor cells. The Journal of Clinical Investigation 101.8 (1998): 1737–744.Google Scholar